Blencowe Resources: Aspiring to become one of the largest graphite producers in the world. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMYT.L Regulatory News (AMYT)

  • There is currently no data for AMYT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Partial Disposal of the Group’s Debt Management Book

14 Nov 2011 07:00

14 November 2011 Sterling Green Group plc ("Sterling Green" or "the Company") Partial Disposal of the Group's Debt Management Book

The Company announces that it has entered into a conditional sale and purchase agreement ("the Sale and Purchase Agreement") to dispose of the majority of its debt management book ("Debt Books) to DRSP Limited , a private limited company whose primary business function is to provide software and support services to the IVA industry ("the Disposal"). Following completion of the proposed Disposal DRSP intends to sub contract the management of the Debt Books to an established third party operating in the debt management sector.

The sale of the Debt Books will be satisfied by an estimated consideration of £ 1.05 million on completion of the proposed Disposal, subject to agreed post completion adjustments.

Under Rule 15 of the AIM Rules, as the Disposal constitutes a fundamental change to the trading business of the Company, the Sale and Purchase Agreement is conditional, inter alia, on the passing of a resolution at a general meeting of the Company to be held at 10.00am on 1 December 2011

Reasons for the Disposal

The Company was admitted to trading on AIM in April 2007 and its strategy at that time was to seek to grow the Group's debt management book with the view to build up an increasing level of monthly recurring income. Whilst the Group has been successful in growing its client base and the associated revenues derived from those clients, it has struggled in a very competitive environment, to generate sufficient income and profits to fully offset the costs associated with the Company being on AIM. The Company has seen a marked increase in costs associated with acquiring robust client leads and in order to grow the business, the Group has taken on debt to fund specific marketing campaigns and/ or payments to lead providers. As a result, the on-going running costs are now at a level that would require substantial growth in the Group's client base in order to continue to be able to service the debt and maintain the Group's lead generation programme. The Directors believe that the Group does not have the necessary capital or ability to raise sufficient capital to compete with other larger competitors and the Disposal represents the best chance for Shareholders to realise some value from their investment in the Company.

Investing Strategy

Following the Disposal, Sterling Green will have limited trading activities, which in the absence of a sale, the Directors anticipate will continue for the foreseeable future. The Group will retain cash balances of approximately £ 500,000 after repaying debt, certain other long term creditors and expenses relating to the Disposal. The Directors believe that the funds which will be in the Company could be attractive to a number of potential acquisition targets seeking admission to AIM by reversing into a liquid cash shell.

The Directors intend to seek to acquire another company or business in exchange for the issue of Ordinary Shares in a single transaction (a "reverse takeover"). The Directors' main investment criteria are that such a company should be:

* a business operating in the Software and Computer Services sector within the UK and Europe; * one which requires little or no funding in excess of the cash resources available to the Company following the Disposal; and * one whose growth prospects, if achieved, will be earnings enhancing for shareholders.

These criteria are not intended to be exhaustive; however the Company may make an investment which does not fulfil all the investment criteria if the Directors believe that it is in the interests of Shareholders as a whole to proceed with such an investment. Any acquisition by the Company will be put to Shareholders for their approval at the appropriate time.

A circular will be sent to shareholders shortly convening a general meeting tobe held on 1 December 2011.J M EdelsonChairman14 November 2011Further enquiries:Sterling Green Group plc Tel: 0161 975 5757 Michael Edelson Merchant Securities Limited Tel: 020 7628 2200 Simon Clements/David Worlidge

XLON
Date   Source Headline
6th Jan 20225:30 pmRNSAmryt Pharma
6th Jan 20227:00 amGNWKey Dates for AIM Delisting
4th Jan 202212:00 pmGNWThe Lancet Diabetes & Endocrinology Publishes Positive Results for the MPOWERED Phase 3 Trial for Mycapssa® (oral octreotide) in Acromegaly Patients
4th Jan 20227:00 amGNWTotal Voting Rights
1st Dec 20217:00 amGNWTotal Voting Rights
30th Nov 20217:00 amGNWDirector/PDMR Shareholding
23rd Nov 202112:00 pmGNWAmryt Provides Update on Regulatory Review Process for Oleogel-S10
22nd Nov 20217:00 amGNWAmryt Announces the Cancellation of Admission of its Ordinary Shares to Trading on AIM
3rd Nov 202111:00 amGNWAmryt Reports Strong Q3 2021 Results
1st Nov 20211:00 pmGNWTotal Voting Rights
1st Nov 20217:00 amRNSAmryt Supports Acromegaly Awareness Day
22nd Oct 20217:00 amRNSAmryt Supports Global EB Awareness Week 2021
20th Oct 202112:00 pmGNWAmryt to Report Q3 2021 Results and Host Conference Call & Webcast on November 3
19th Oct 202112:00 pmGNWAmryt Announces New Patents for Oleogel-S10 and Mycapssa®
23rd Sep 202112:00 pmRNSAmryt Supports Global FH Awareness Day
13th Sep 202112:00 pmGNWAmryt Raises Full Year 2021 Revenue Guidance to $220M - $225M
1st Sep 20217:00 amGNWTotal Voting Rights
19th Aug 20217:00 amGNWAmryt Issues Ordinary Shares and Total Voting Rights
13th Aug 20211:23 pmRNSHolding(s) in Company - Replacement
11th Aug 202111:30 amRNSHoldings in Company
11th Aug 202110:36 amRNSHolding(s) in Company
10th Aug 20212:20 pmGNWDirector/PDMR Shareholding
10th Aug 20219:53 amRNSHolding(s) in Company
9th Aug 202112:00 pmGNWAmryt Virtual Capital Markets Event - September 13, 2021 – 1000-1200 EDT
6th Aug 202112:00 pmGNWAmryt Reports Record Q2 2021 Results and Raises FY 2021 Guidance
5th Aug 20213:50 pmGNWAmryt Successfully Completes Acquisition of Chiasma, Inc., Board Appointments, Issues Ordinary Shares and Total Voting Rights
28th Jul 20213:00 pmGNWResult of General Meetings
12th Jul 202112:00 pmGNWAmryt to Report Q2 2021 Results and Host Conference Call & Webcast on August 6
28th Jun 202112:00 pmGNWPublication of Circular to Amryt Shareholders in relation to the acquisition of Chiasma, Inc., and posting of Annual Report and Notices of General Meetings
15th Jun 202111:45 amGNWAmryt Pharma Announces Filing of Preliminary Registration Statement on Form F-4 in Connection with Its Proposed Acquisition of Chiasma, Inc.
7th Jun 202112:00 pmGNWFDA confirms NDA for Oleogel-S10 will not require an Advisory Committee Meeting
3rd Jun 20217:00 amGNWFDA Grants Priority Review for New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa
2nd Jun 20211:30 pmGNWAmryt Announces FDA Acceptance of New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa
5th May 20214:41 pmRNSSecond Price Monitoring Extn
5th May 20214:35 pmRNSPrice Monitoring Extension
5th May 202112:05 pmGNWAmryt Reports Record Q1 2021 Financial and Operating Results
5th May 202112:00 pmGNWAmryt Pharma to Acquire Chiasma, Inc. to Further Strengthen Global Leadership in Rare and Orphan Diseases
15th Apr 202112:00 pmGNWAmryt to Report Q1 2021 Results and Host Conference Call & Webcast on May 5
6th Apr 20217:00 amGNWAmryt Announces the Appointment of Sheila Frame as President Americas
31st Mar 202111:00 amRNSAmryt Supports World Lipodystrophy Day
31st Mar 20217:00 amGNWAmryt Submits a New Drug Application to the US Food and Drug Administration for Oleogel-S10* (Filsuvez®)
30th Mar 20217:00 amGNWAmryt Announces Results from an Investigator Sponsored Study of Lomitapide in FCS
29th Mar 20217:00 amGNWAmryt Announces Validation of its MAA by the EMA for Oleogel-S10* (Filsuvez®)
23rd Mar 20217:00 amGNWAmryt Receives Positive Feedback from the FDA on the Path Forward for Myalept® (metreleptin) Indication in Partial Lipodystrophy
22nd Mar 20217:00 amGNWAmryt Receives Reimbursement Approval from the French Ministry of Social Affairs and Health for Myalepta® (metreleptin)
15th Mar 202110:00 amGNWDirector/PDMR Shareholding
12th Mar 20217:00 amGNWExercise of Options and Total Voting Rights
11th Mar 202111:30 amGNWExercise of Warrants & Issue of Ordinary Shares and Total Voting Rights
8th Mar 20216:00 pmGNWDirector/PDMR Shareholding
8th Mar 20217:00 amGNWAmryt and Medison Pharma Sign Distribution Agreement for Myalepta® (metreleptin) in Canada

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.